DK1716233T3 - Reguleret stopkodongennemlæsning - Google Patents

Reguleret stopkodongennemlæsning

Info

Publication number
DK1716233T3
DK1716233T3 DK05700620T DK05700620T DK1716233T3 DK 1716233 T3 DK1716233 T3 DK 1716233T3 DK 05700620 T DK05700620 T DK 05700620T DK 05700620 T DK05700620 T DK 05700620T DK 1716233 T3 DK1716233 T3 DK 1716233T3
Authority
DK
Denmark
Prior art keywords
polypeptide
stop codon
interest
cells expressing
cells
Prior art date
Application number
DK05700620T
Other languages
Danish (da)
English (en)
Inventor
Thomas Bouquin
Original Assignee
Maxygen Holdings Ltd
Maxygen Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34830514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1716233(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Maxygen Holdings Ltd, Maxygen Aps filed Critical Maxygen Holdings Ltd
Application granted granted Critical
Publication of DK1716233T3 publication Critical patent/DK1716233T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
DK05700620T 2004-01-30 2005-01-28 Reguleret stopkodongennemlæsning DK1716233T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54082004P 2004-01-30 2004-01-30
US63130604P 2004-11-29 2004-11-29
PCT/DK2005/000070 WO2005073375A1 (en) 2004-01-30 2005-01-28 Regulated stop codon readthrough

Publications (1)

Publication Number Publication Date
DK1716233T3 true DK1716233T3 (da) 2009-10-26

Family

ID=34830514

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05700620T DK1716233T3 (da) 2004-01-30 2005-01-28 Reguleret stopkodongennemlæsning

Country Status (7)

Country Link
US (1) US20070224635A1 (de)
EP (1) EP1716233B1 (de)
AT (1) ATE440949T1 (de)
DE (1) DE602005016218D1 (de)
DK (1) DK1716233T3 (de)
ES (1) ES2329807T3 (de)
WO (1) WO2005073375A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825231B2 (en) 2005-06-01 2010-11-02 Darren P. Wolfe Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
WO2007047706A2 (en) * 2005-10-17 2007-04-26 Children's Hospital Methods and compositions for regulating gene expression
DK2329020T3 (da) * 2008-08-28 2013-06-10 Novartis Ag Celleoverfladepræsentation af polypeptidisoformer ved hjælp af stopcodon-overspringelse
US20110165583A1 (en) * 2008-09-02 2011-07-07 Lupin Limited Vector for identification, selection and expression of recombinants
CA2753814C (en) 2009-02-27 2018-07-31 Novartis Ag Novel selection vectors and methods of selecting eukaryotic host cells
WO2011140529A1 (en) * 2010-05-07 2011-11-10 Lakepharma, Inc. Surface markers and uses thereof for rapid stable cell line generation and gene amplification
EP2569331A1 (de) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptid-inhibitoren von vla4
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (de) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2014058982A2 (en) * 2012-10-10 2014-04-17 Temple University Of The Commonwealth System Of Higher Education Nuclear factor-erythroid 2 related factor 2 (nrf2) biosensors and modulators of nrf2
WO2014066404A2 (en) * 2012-10-22 2014-05-01 Life Technologies Corporation System and method for visualization of optimized protein expression
CA2891388C (en) 2012-11-20 2021-09-14 Novartis Ag Optimized expression cassette for expressing a polypeptide with high yield
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
WO2014085711A1 (en) * 2012-11-30 2014-06-05 Larix Biosciences Llc A novel cell line screening method
EP2970956A1 (de) 2013-03-11 2016-01-20 Novartis AG Verfahren zum screening von zellklonen
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20140323315A1 (en) 2013-04-29 2014-10-30 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
PT3027646T (pt) 2013-07-31 2018-10-16 Novartis Ag Novos vetores e métodos de seleção de células hospedeiras eucarióticas
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2015092735A1 (en) 2013-12-20 2015-06-25 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
ES2758505T3 (es) 2013-12-20 2020-05-05 Novartis Ag Células eucariotas novedosas y métodos para expresar de forma recombinante un producto de interés
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
US20240148903A1 (en) * 2021-03-08 2024-05-09 Nanjing GenScript Biotech Co., Ltd. Delivery of antibody by using dual viral vector system
IL309179A (en) * 2021-06-10 2024-02-01 Janssen Biotech Inc Nucleic acid coding for KLK2-GPI fusion protein, recombinant cells and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264341A (en) * 1989-08-30 1993-11-23 Eli Lilly And Company Selective cloning for high monoclonal antibody secreting hybridomas
ES2168277T3 (es) * 1992-09-04 2002-06-16 Scripps Research Inst Fagemidos que coexpresan un receptor de superficie y una proteina heterologa de superficie.
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
US20020086427A1 (en) * 2000-03-23 2002-07-04 Leiden Jeffrey M. Inducible eukaryotic expression system that regulates protein translation
DE10053224A1 (de) * 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
EP1451344A4 (de) * 2001-05-21 2005-03-23 Invitrogen Corp Zusammensetzungen und verfahren zur verwendung bei der isolierung von nukleinsäuremolekülen
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
WO2003014361A1 (en) * 2001-08-02 2003-02-20 Altana Pharma Ag Novel recombinant gene expression method by stop codon suppression
ATE476503T1 (de) * 2001-10-01 2010-08-15 Deutsches Krebsforsch Verfahren zur herstellung von protein- bibliotheken und zur selektion von proteinen daraus
US20040101823A1 (en) * 2001-12-21 2004-05-27 Maxygen, Inc. HIV-1 viral variants for improved animal models of HIV-1 pathogenesis
US7833741B2 (en) * 2002-08-07 2010-11-16 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
ES2408582T3 (es) * 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos

Also Published As

Publication number Publication date
DE602005016218D1 (de) 2009-10-08
EP1716233A1 (de) 2006-11-02
ATE440949T1 (de) 2009-09-15
WO2005073375A1 (en) 2005-08-11
US20070224635A1 (en) 2007-09-27
EP1716233B1 (de) 2009-08-26
ES2329807T3 (es) 2009-12-01

Similar Documents

Publication Publication Date Title
DK1716233T3 (da) Reguleret stopkodongennemlæsning
Baiocchini et al. Extracellular matrix molecular remodeling in human liver fibrosis evolution
Kaisermann et al. Fungal communities are more sensitive indicators to non-extreme soil moisture variations than bacterial communities
Cohen-Salmon et al. Connexin30 deficiency causes instrastrial fluid–blood barrier disruption within the cochlear stria vascularis
Martinez-Caballero et al. Tim17p regulates the twin pore structure and voltage gating of the mitochondrial protein import complex TIM23
WO2007047578A3 (en) Cell display of antibody libraries
MX2025015600A (es) Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular
PH12012501436A1 (en) Combined used of cry1da and cry1fa proteins for insect resistance management
TW200833713A (en) Human antibodies that bind CD19 and uses thereof
EA200600345A1 (ru) Способ культивирования клеток
WO2014035693A3 (en) Methods and compositions related to modulators of eukaryotic cells
MA28943B1 (fr) Corps mimetiques de liaison au recepteur de la melanocortine, compositions, procedes et utilisations
RU2010129550A (ru) Органические соединения
DE602005016707D1 (de) Stabile genomische integration mehrerer polynukleotidkopien
DE60232234D1 (de) Verfahren zur kultivierung von circovirus
WO2005072129A9 (en) Production of host cells containing mutiple integrating vectors by serial transduction
WO2010059981A3 (en) High complexity mammalian display library and methods of screening
WO2008060483A3 (en) Protein-protein interaction biosensors and methods of use thereof
MX2008001513A (es) Secuencias de acidos nucleicos que codifican proteinas asociadas con respuesta a estres abiotico y celulas vegetales y plantas con aumento de tolerancia a estres ambiental.
WO2007051063A3 (en) Gpcr expressing cell lines and antibodies
DK1743029T3 (da) Cellefremstilling
WO2006066229A3 (en) Elicitation of antibodies to self peptides by immunization with dendritic cells
Schlagintweit et al. Perturbatacrusta leini n. gen., n. sp. a new microencruster incertae sedis (? sponge) from Late Jurassic to earliest Cretaceous platform margin carbonates of the Northern Calcareous Alps of Austria
SI2084529T1 (sl) Stabilne celične linije in postopki za evaluacijo gastrointestinalne absorpcije kemikalij
WO2010013934A2 (ko) 세포외기질 성분을 함유하는 노화조절용 조성물 및 이를 이용한 노화세포의 노화조절방법